Drugs / Investigational TIV-HD2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03282240 Comparator | Sep → Nov 2017 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational TIV-HD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282240 ↗ |
| Modality | Vaccine | “an IIV3-HD containing the alternate B-lineage strain” PMID 31431411 ↗ Aug 2019 |
| Route | Intramuscular | “administered IM into the upper arm area” NCT03282240 ↗ |